Hester Biosciences credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
188188208239268
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
182182201224253
0.51×0.51×0.64×0.79×0.93×
0.49×0.49×0.61×0.74×0.88×
2.17×2.17×3.40×4.46×5.30×
2.10×2.10×3.29×4.17×5.01×
6.20×6.20×3.48×1.84×3.21×
33.9%33.9%38.9%44.1%48.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HESTERBIO₹2,054.00

Hester Biosciences Limited

· Pharma & Health
₹ CrorePeersWINDLASSYNCOMFNGLFINEINDOCOSAIPARENTJAGSNPHARMPANACEABIOMcap ₹1,747 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt268.2239.0207.8188.3188.3
Net Debt253.3223.7200.6181.7181.7
Total Debt/Equity0.930.790.640.510.51
Net Debt/Equity0.880.740.610.490.49
Total Debt/EBITDA5.304.463.402.172.17
Net Debt/EBITDA5.014.173.292.102.10
Interest Coverage (EBIT/Interest)3.211.843.486.206.20
Total Debt/Total Capital %48.1744.1138.8833.8633.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.